Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results